How to buy Celyad Oncology stock

Celyad Oncology SA is a biotechnology business based in the US. Celyad Oncology shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad Oncology employs 87 staff and has a trailing 12-month revenue of around USD$5,000.

How to buy shares in Celyad Oncology

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Celyad Oncology. Find the stock by name or ticker symbol: CYAD. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Celyad Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Celyad Oncology, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Celyad Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Celyad Oncology share price

Use our graph to track the performance of CYAD stocks over time.

Celyad Oncology shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$6.81 - USD$13.01
50-day moving average	USD$7.3461
200-day moving average	USD$8.1769
Wall St. target price	USD$19.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-7.007

Buy Celyad Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Celyad Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Celyad Oncology SA by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celyad Oncology financials

Revenue TTM	USD$5,000
Gross profit TTM	USD$5,000
Return on assets TTM	-21.04%
Return on equity TTM	-44.91%
Profit margin	0%
Book value	$2.223
Market capitalisation	USD$102.3 million

TTM: trailing 12 months

Shorting Celyad Oncology shares

There are currently 209,905 Celyad Oncology shares held short by investors – that's known as Celyad Oncology's "short interest". This figure is 0.2% down from 210,285 last month.

There are a few different ways that this level of interest in shorting Celyad Oncology shares can be evaluated.

Celyad Oncology's "short interest ratio" (SIR)

Celyad Oncology's "short interest ratio" (SIR) is the quantity of Celyad Oncology shares currently shorted divided by the average quantity of Celyad Oncology shares traded daily (recently around 12599.339735894). Celyad Oncology's SIR currently stands at 16.66. In other words for every 100,000 Celyad Oncology shares traded daily on the market, roughly 16660 shares are currently held short.

However Celyad Oncology's short interest can also be evaluated against the total number of Celyad Oncology shares, or, against the total number of tradable Celyad Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celyad Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Celyad Oncology shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Celyad Oncology shares, roughly 0 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Celyad Oncology.

Find out more about how you can short Celyad Oncology stock.

Celyad Oncology share dividends

We're not expecting Celyad Oncology to pay a dividend over the next 12 months.

Celyad Oncology share price volatility

Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $6.81 up to $13.01. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.4889. This would suggest that Celyad Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celyad Oncology overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .

Frequently asked questions

• What percentage of Celyad Oncology is owned by institutions?

  Currently 7.467% of Celyad Oncology shares are held by institutions.

• How many people work for Celyad Oncology?

  Latest data suggests 87 work at Celyad Oncology.

• When does the fiscal year end for Celyad Oncology?

  Celyad Oncology's fiscal year ends in December.

• Where is Celyad Oncology based?

  Celyad Oncology's address is: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435

• What is Celyad Oncology's ISIN number?

  Celyad Oncology's international securities identification number is: US1512052002

• What is Celyad Oncology's CUSIP number?

  Celyad Oncology's Committee on Uniform Securities Identification Procedures number is: 151205200